Novel agents for the control of secretory diarrhoea

Bibliography

• FARTHING MJG: Acute diarrhea: pathophysiology. In: Diarrhea] Disease (Vol. 38). M Gracey, JA Walker-Smith (Eds), Vevey/Lippincott-Raven Publishers, Philadelphia (1997):55–71.
   Google Scholar
• FARTHING MJG: Pathophysiology of infective diarrhoea. Ear: Gastroenterol Hepatol (1993) 5:796–807.
   Web of Science ®Google Scholar
• PARASHAR UD, BRESEE JS, GLASS RI: The global burden of diarrhoeal disease in children. Buff World Health Organ. (2003) 81:236.
   PubMed Web of Science ®Google Scholar
• •Review of the burden of diarrhoeal disease in children.
   Google Scholar
• FARTHING MJG: Dehydration and rehydration in children. In: Hydration Throughout Life. MJ Arnaud (Ed.), John Libbey Eurotext, Paris (1998):159–173.
   Google Scholar
• RAO MC: Molecular mechanisms of bacterial toxins. In: Enteric infection. MJG Farthing, GT Keusch (Eds), Chapman & Hall, London (1989):87–104.
   Google Scholar
• FIELD M, FAO MC, CHANG EB: Intestinal electrolyte transport and diarrheal disease. N Engl. Med. (1989) 321:879–883.
   PubMed Web of Science ®Google Scholar
• FIELD M, RAO MC, CHANG EB: Intestinal electrolyte transport and diarrheal disease. N Engl. Med. (1989) 321:800–806.
   PubMed Web of Science ®Google Scholar
• RAO MC: Toxins which activate guanylate cyclase: heat-stable enterotoxins. In: Microbial Toxins and Diarrhoea] Disease. D Evered, J Whelan (Eds), Ciba Foundation Symposium 112, Pitman, London (1985):74–93.
   Google Scholar
• ZHANG M, ZENG CO-Y, MORRIS AP, ESTES MK: A functional N594 enterotoxin peptide secreted from rotavirus- infected cells.Vim]l (2000) 74: 11663-11670.
   Google Scholar
• •Description of a novel viral enterotoxin.
   Google Scholar
• MOHAN KVK, DERMODY TS, ATREYA CD: Mutations selected in rotavirus enterotoxin NSP4 depend on the context of its expression. Virology (2000) 275:125–132.
   PubMed Web of Science ®Google Scholar
• MORRIS AP, ESTES MK: Microbes andmicrobial toxins: Paradigms for microbial-mucosal interactions VIII. Pathological consequences of rotavirus infection and its enterotoxin. Am. Physic] (2001) 281:G303–G310.
   Google Scholar
• FARTHING MJG: 5-Hydroxytryptamine and 5-hydroxytryptamine 3 receptor antagonists. Scandj Gastroenterol (1991) 188(Suppl.):92–100.
   Google Scholar
• NILSSON 0, CASSUTO J, LARSSON PA et al.: 5-Hydroxytryptamine and cholera secretion: a histochemical and physiological study in cats. Gut (1983) 24:542–548.
   Google Scholar
• MUNCK LK, MERTZ-NIELSON A, WEST H, BUKHAVE K, BEUBLER E, RASK-MADSEN J: Prostaglandin E2 is a mediator of 5-hydroxytryptamine induced water and electrolyte secretion in the human jejunum. Gut (1988) 29:1337–1341.
   PubMed Web of Science ®Google Scholar
• BEUBLER E, KOLLAR G, SARIA A, BUKHAVE K, RASK-MADSEN J: Involvement of 5-hydroxytryptamine, prostaglandin E2 and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of the rat in vivo. Gastroenterology (1989) 96:368–376.
   PubMed Web of Science ®Google Scholar
• BEARCROFT CP, PERRETT D, FARTHING MJG: 5-Hydroxytryptamine release into human jejunum by cholera toxin. Gut (1996) 39:528–531.
   PubMed Web of Science ®Google Scholar
• ••First description of the release of 5-HT byCTs in humans.
   Google Scholar
• BEUBLER E, HORINA G: 5-HT2 and 5-HT3 receptor subtypes mediate cholera toxin-induced intestinal fluid secretion. Gastroenterology (1990) 99:83–89.
   PubMed Web of Science ®Google Scholar
• SJOQVIST A, CASSUTO J, JODAL M, LUNDGREN 0: Actions of serotonin antagonists on cholera-induced intestinal fluid secretion. Acta Physiol Scand. (1992) 145:229–237.
   PubMedGoogle Scholar
• MOURAD FH, O'DONNELL LJ, DIAS JA et al: Role of 5-hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and Escherichia coil enterotwdns. Gut (1995) 37:340–345.
   PubMed Web of Science ®Google Scholar
• BEUBLER E, SCHULIGOI R, CHOPRA AK, RIBARDO DA, PESKAR BA: Cholera toxin induces prostaglandin synthesis via post-transcriptional activation of cyclooxygenase-2 in the rat jejunum. .1. Path. Exp. Therap. (2002) 297:940–945.
   Web of Science ®Google Scholar
• TURVILL JL, FARTHING MJG: Substance P (SP) antagonist inhibits cholera toxin but not E. coil enterotoxin-induced secretion. Gastroenterology (1999) 112:A414.
   Web of Science ®Google Scholar
• TURVILL JL, CONNOR P, FARTHING MJG: Neurokinin 1 and 2 receptors mediate cholera toxin secretion in rat jejunum. Gastroenterology (2000) 119:1037–1044.
   PubMed Web of Science ®Google Scholar
• POTHOULAKIS H, CATAGLIUOLO I, LAMONT T et al.: ICP-96,345, a substance P antagonist inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc. Nat] Acad. Sci. USA (1994) 91:947–951.
   PubMed Web of Science ®Google Scholar
• CASTAGLUIOLO I, LAMONT JT, LETOURNEAU R et al.: Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio enterotoxin in rat ileum. Gastroenterology (1994) 107:657–665.
   PubMed Web of Science ®Google Scholar
• FARTHING MICHAEL JG: Novel targets for the pharmacotherapy of diarrhoea - a view for the millennium. Gastroenterol Hepatol (2000) 15(Suppl.):C40–C47.
   Google Scholar
• FARTHING MJG: Novel targets for the control of secretory diarrhoea. Gut (2002) 50 (Suppl. 3):1–3.
   Google Scholar
• FARTHING MJG, CASBURN-JONES A, BANKS MR: Getting control of intestinal secretion: thoughts for 2003. Dig. Liv. Dis. (2003) 35:378–385.
   Web of Science ®Google Scholar
• HUBEL KA: Intestinal nerves and ion transport: stimuli, reflexes and responses. Am. Physic] (1985) 248:G261–G271.
   PubMed Web of Science ®Google Scholar
• JODAL M: Neuronal influence on intestinal transport. Intern. Med. (1990) 228:125–132.
   Web of Science ®Google Scholar
• COOKE HJ: Neurotransmitters in neuronal reflexes regulating intestinal secretion. Ann. NY Acad. Sri. (2000) 915:77–80.
   PubMed Web of Science ®Google Scholar
• POTHOULAKIS C: The role of neuroenteric hormones in intestinal infectious diseases. Carr: Opin. Gastroenterol (2000) 16:536–540.
   PubMed Web of Science ®Google Scholar
• BANKS MR, CASBURN-JONES AC, FARTHING MJG: Cholera toxin (CT), Escherichia coil heat labile (LT) and heat stable toxin (STA) have an indirect effect on distal intestinal fluid transport in the rat small intestine. Gut (2002) (Suppl. II) A69.
   Google Scholar
• CASBURN-JONES AC, BARNETT SC, FITZGERALD UF, FARTHING MJG: Cholera toxin (CT) Escherichia coil heat labile toxin (LT) and heat stable toxin (STA) have a direct effect on the neuronal-like PC12 cell line. Gut (2002) (Suppl. II) A26.
   Google Scholar
• CASBURN-JONES AC, BARNETT SC, FARTHING MJG: Bacterial enterotwdns stimulate release of the neurotransmitter [3H1 noradrenaline from neuronally differentiated PC 12 cells. Gut (2004) (In press).
   Google Scholar
• CASBURN-JONES AC, YOUNG C, HERZYK P, RIBOLDI-TUNNICLIFFE G, FARTHING MJG: Identification of differentially expressed genes following bacterial enterotoxin-induced neuronal growth and differentiation in PC12 cells. Gut (2004) (In press).
   Google Scholar
• LUNDGREN 0, PEREGRIN AT, PERSSON K, KORDASTI S, UHNO0 I, SVENSSON L: Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea. Science (2000) 287:491–495.
   PubMed Web of Science ®Google Scholar
• ••First description of the role of ENS in amodel of rotavirus diarrohea.
   Google Scholar
• JODAL M: Neuronal influence on intestinal transport. J. Intern. Med. (1990) 228:125–132.
   PubMed Web of Science ®Google Scholar
• CASSUTO J, FAHRENKRUG J, JODAL M, TUTTLE R, LUNDGREN 0: Release of vasoactive intestinal polypeptide from the cat small intestine exposed to cholera toxin. Gut (1981) 22:958–963.
   PubMed Web of Science ®Google Scholar
• TURVILL JL, CONNOR P, FARTHING MJG: The inhibition of cholera toxin-induced 5-HT release by the 5-HT3 receptor antagonist, granisetron, in the rat. Br. J. Pharmacol (2000)130:1031–1036.
   PubMed Web of Science ®Google Scholar
• MOURAD FH, NASSAR C: Effect of vasoactive intestinal peptide (VIP) antagonism on rat jejunal fluid and electrolyte secretion induced by cholera and Escherichia colienterotoxins. Gut (2000) 47:382–386.
   PubMed Web of Science ®Google Scholar
• BANKS MR, FARTHING MJG, ROBBERECHT P, BURLEIGH DE: Anti-secretory actions of a novel vasoactive intestinal polypeptide receptor antagonist. Gastroenterology (2002) 122(4):A254.
   Web of Science ®Google Scholar
• TURVILL JL, KASAPIDIS P, FARTHING MJG: The sigma ligand, igmesine, inhibits cholera toxin and Escherichia colienterotoxin induced jejunal secretion in the rat. Gut (1999) 45:564–569.
   PubMed Web of Science ®Google Scholar
• FARTHING MJG: The role of somatostatin analogues in the treatment of refractory diarrhoea. Digestion (1996) 57:107–112.
   PubMed Web of Science ®Google Scholar
• FRIED M: Octreotide in the treatment ofrefractory diarrhea. Digestion (1999) 60:42–46.
   PubMed Web of Science ®Google Scholar
• ABBAS Z, MOID I, KHAN AH et al: Efficacy of octreotide in diarrhoea due to Vibrio cholerae: a randomized, controlled trial. Ann. Bop. Med. Parasitol (1996) 90:507–513.
   PubMed Web of Science ®Google Scholar
• GARCIA COMPEAN D, RAMOS JIMENEZ J, GUZMAN DE LA GARZA F et al: Octreotide therapy of large-volume refractory AIDS-asociated diarrhea: a randomized controlled trial. AIDS (1994) 8:1563–1567
   PubMed Web of Science ®Google Scholar
• SZILAGYI A, SHRIER I: Systematic review: the use of somatostatin or octreotide in refractory diarrhoea. Aliment. Pharmacol Therap. (2001) 15:189–197.
   Google Scholar
• TURVILL JL, FARTHING MJG: Enkephalins and enkephalinase inhibitors in intestinal fluid and electrolyte transport. Eur. J. Castro. Hepatol (1997) 9:877–880.
   PubMed Web of Science ®Google Scholar
• FARTHING MJG: Enkephalinase inhibition: a rational approach to anti-secretory therapy for acute diarrhoea. Aliment. Pharmacol Ther. (1999) 13 (Suppl. 6):1–2.
   Google Scholar
• PRIMI MP, BEUNO L, BAUMER P, BERARD H, LECOMTE JE: Racecadotril demontrates intestinal anti-secretory activity IP vivo. Aliment. Pharmacol Ther. (1999) 13\(Suppl. 6):3–7.
   Google Scholar
• HAMZA H, KHALIFA HB, BAUMER P, BERARD H, LECOMTE JM: Racecadotril versus placebo in the treatment of acute diarrhoea in adults. Aliment. Pharmacol Ther: (1999) 13 (Suppl. 6):15–19.
   Google Scholar
• LECOMTE JM: An overview of clinical studies with racecadotril in adults. Int. J. Antimicrob. Agents (2000) 14:81–87
   PubMed Web of Science ®Google Scholar
• PRADO D: A multinational comparison of racecadotril and loperamide in the treatment of watery diarrhoea in adults. Scandj Gastroenterol (2002) 37:656–661.
   PubMed Web of Science ®Google Scholar
• TURCK D, BERARD H, FRETAULT N, LECOMTE JM: Comparison of racecadotril and loperamide in children with acute diarrhoea. Aliment. Pharmacol Ther: (1999) 13 (Suppl. 6):27–32.
   Google Scholar
• CEZARD JP, DUHAMEL JF, MEYER M et al: Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterology (2001) 120:799–805
   PubMed Web of Science ®Google Scholar
• SALAZAR-LINDO E, SANTISTEBAN-PONCE J, CHEA-WOO E, GUTIERREZ M: Racecadotril in the treatment of acute watery diarrhea in children. N Engl. I Med. (2000) 343:463–467.
   PubMed Web of Science ®Google Scholar
• ••Clinical efficacy of a new enkephalinase inhibitor in children. Important efficacy outcome is reduced faecal weight.
   Google Scholar
• POWELL DW, FIELD M: Pharmacological approaches to treatment of secretory diarrhoea. In: Secretory Diarrhea. M Field, JS Fordtran, SG Schultz (Eds), American Physiological Society, Bethesda, MD, USA (1980):187–209.
   Google Scholar
• AIKAWA N, KARASAWA A, OHMORI K: Effect of zaldaride maleate, an antidiarrheal compound, on intracellular cyclic nucleotide-mediated intestinal ion secretion in rats. Ear. Pharmacol (2000) 394:233–236
   PubMed Web of Science ®Google Scholar
• SILBERSCHMIDT G, SCHICK MT, STEFFEN R et al :Treatment of traveller's diarrhoea: zaldaride compared with loperamide and placebo. Ear. J. Gastroenterol Hepatol (1995) 7:871–875.
   PubMed Web of Science ®Google Scholar
• OKHUYSEN PC, DUPONT HL, ERICSSON CD et al.: Zaldaride maleate (a new calmodulin antagonist) versus loperamide in the treatment of traveler's diarrhoea: a randomised, placebo-controlled trial. Clin. Infect. D (1995)21:341–344.
   PubMed Web of Science ®Google Scholar
• SCHULTZ BD, SINGH AK, DEVOR DC, BRIDGES RJ: Pharmacology of CFTR chloride channel activity. Physiol Rev (1999) 79\(Suppl. 1):5109–5144
   Google Scholar
• CAI Z, LANDSELL KA, SHEPPARD DN: Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulatorchannels by non- sulphonylurea hypoglycaemic agents. Br. .1. Pharmacol (1999)128:108–118.
   PubMed Web of Science ®Google Scholar
• MAT, THIAGARAJAH JR, YANG H, et al: Thiazolidinone CFTR inhibitor identified by high throughput screening blocks cholera toxin-induced intestinal fluid secretion. J. Clin. Invest. (2002) 110:1651–1658.
   PubMed Web of Science ®Google Scholar
• DICESARE D, DUPONT HL, MATHEWSON JJ et al.: A double-blind, randomized, placebo-controlled study of SP 303 (provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am. .1 Gastroenterol (2002)97:2585–2588.
   Google Scholar
• THEODOROU V, CHOVET M, EUTAMENE H et al: Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action. Gut (2002)51:522–528
   Google Scholar
• ROZE C, BRULEY DES VARANNES S, SHI G, GENEVE J, GALMICHE JP: Inhibition of prostaglandin-induced intestinal secretion by igmesine in healthy volunteers. Gastroenterology (1998)115:591–596.
   PubMed Web of Science ®Google Scholar
• BEUBLER E, HORINA G: 5-HT3 receptorsubtypes mediate cholera toxin-induced intestinal fluid secretion in the rat. Gastroenterology (1990) 99:83–89.
   PubMed Web of Science ®Google Scholar
• BUCHHEIT KH: Inhibition of cholera toxin-induced intestinal secretion by the 5-HT3 receptor antagonist ICS 205-930. Arch. Phanmacol (1989) 339:704–705.
   Google Scholar
• EHERE AJ, HINTERLEITNER TA, PETRITSCH W, HOLZER PETSCHE U, BEUBLER E, KREJS GJ: Effect of 5-hydroxytryptamine antagonists on cholera toxin-induced secretion in the human jejunum. Eur.j Clin. Invest. (1994) 24:664–668.
   PubMed Web of Science ®Google Scholar
• BEARCROFT CP, ANDRE E, FARTHING MJG: Li vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion. Aliment. Pharm. Therap. (1997) 11:1109–1114.
   PubMed Web of Science ®Google Scholar
• TURVILL JL, FARTHING MJG: Effect ofgranisetron on cholera toxin-induced enteric secretion. Lancet (1997) 349:1293.
   PubMed Web of Science ®Google Scholar
• •Demonstration of antisecretory activity of a 5-HT3 receptor antagonist in humans.
   Google Scholar
• TURVILL JL, FARTHING MJG: Selective 5-hydroxytryptamine type 4 (5-HT4) antagonist inhibits cholera toxin (CT) but not Ecoli heat labile toxin (LT)-induced secretion. Gastroenterology (1996) 110:A368.
   Web of Science ®Google Scholar